Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female invasive ductal carcinomas

Breast Cancer

Volumn 15, Issue 3, 2008, Pages 231-240

  Taniyama, Kiyomi ^a   Ishida, Katsunari ^a   Toda, Tamaki ^a   Motoshita, Junichi ^a   Kuraoka, Kazuya ^a   Saito, Akihisa ^a   Tani, Yoichi ^b   Uike, Toshinori ^a   Teramoto, Seiichi ^a   Koseki, Masato ^a  

^a NATIONAL HOSPITAL ORGANIZATION   (Japan)

^b DakoCytomation Co Ltd   (Japan)

Author keywords

Breast; Gene amplification; HER2; Phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TYROSINE;

ADULT; AGED; ARTICLE; BREAST TUMOR; ENZYME IMMUNOASSAY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PHOSPHORYLATION; PROTO ONCOGENE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; PHOSPHORYLATION; RECEPTOR, ERBB-2; TYROSINE;

EID: 59149086374     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-007-0026-8     Document Type: Article

References (21)

1. Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo and heterodimers. Mol Cell Biol. 1999;19:6845-57. (Pubitemid 29441868)
2. Lohrisch C, Piccart M. An overview of HER2. Semin Oncol. 2001;28(Suppl 18):3-11. (Pubitemid 34062043)
3. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2005;123:766-70. (Pubitemid 40586495)
4. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/ College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med. 2007;131:18.
5. Thor AD, Liu S, Edgerton S, Moore D 2nd, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230-9.
6. The Japanese Breast cancer Society. General Rules for Clinical and Pathological Recording of Breast Cancer (in Japanese), 15th edn. Tokyo: Kanehara.
7. Tavassoli FA, Devilee P. WHO classification of tumours, pathology and genetics, tumours of the breast and female genital organs. Lyon: IARC press; 2002.
8. American Joint Committee on Cancer. AJCC cancer staging manual. 6th edn. New York: Springer; 2002.
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administrationapproved scoring system. J Clin Oncol. 1999;17:1983-7. (Pubitemid 29318825)
10. Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005;11:8348-57. (Pubitemid 41746947)
11. Moore JG, To V, Patel SJ, Sneige N. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparison with companion tissue sections. Diagn Cytopathol. 2000;23:299-302.
12. Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-64.
13. Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathol Int. 2001;51:33-6. (Pubitemid 32158809)
14. Lottner C, Schwarz S, Diermeier S, Hartmann A, Knuechel R, Hofstaedter F, Brockhoff G. Simultaneous detection of HER2/ neu gene amplification and protein overexpression in paraffinembedded breast cancer. J Pathol. 2005;205:577-84. (Pubitemid 40514830)
15. Hashizume K, Hatanaka Y, Kamihara Y, Tani Y. Automated immunohistochemical staining of formalin-fixed and paraffinembedded tissues using a catalyzed signal amplification method. Appl Immunohistochem Mol Morphol. 2001;9:54-60. (Pubitemid 32179111)
16. Taniyama K, Goodison S, Ito R, Bookstein R, Miyoshi N, Tahara E, Tarin D, Urquidi V. PTEN expression is maintained in sporadic colorectal tumours. J Pathol. 2001;194:341-8. (Pubitemid 32624561)
17. Hudelist G, Kostler WJ, Attems J, Czerwenka K, Muller R, Manavi M, Steger GG, Kubista E, Zielinski CC, Singer CF. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer. 2003;89:983-91. (Pubitemid 37239199)
18. Chen JS, Lan K, Hung MC. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resist Updat. 2003;6:129-36. (Pubitemid 36890337)
19. Chan CT, Metz MZ, Kane SE. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors. Breast Cancer Res Treat. 2005;91:187-201. (Pubitemid 40684931)
20. Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/ activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest. 2005;23:483-7. (Pubitemid 41463863)
21. Li X, Lu Y, Liang K, Liu B, Fan Z. Differential responses to doxorubicin-induced phosphorylation and activation of Akt in human breast cancer cells. Breast Cancer Res. 2005;7:R589-97.